The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | A trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in R/R MDS
Ian Bouligny, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the results of a Phase II trial (NCT02530463) investigating the combination of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in patients with relapsed/refractory (R/R) myelodysplastic syndrome (MDS). Dr Bouligny notes that the trial showed modest response rates, with no significant differences in overall response rates between the different treatment arms, and that the addition of azacitidine did not improve response rates in patients who had progressed on immunotherapy. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
